A renal transplant recipient with pulmonary tuberculosis and visceral leishmaniasis: review of superimposed infections and therapy approaches

التفاصيل البيبلوغرافية
العنوان: A renal transplant recipient with pulmonary tuberculosis and visceral leishmaniasis: review of superimposed infections and therapy approaches
المؤلفون: Kamil Dilek, Ylmaz E, Bülent Oktay, Ozçelik T, Hakan Vuruşkan, Mehmet Usta, Alpaslan Ersoy, Mahmut Yavuz, Uzaslan Ek, Mustafa Güllülü, Mustafa Yurtkuran
المصدر: Clinical nephrology. 60(4)
سنة النشر: 2003
مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, business.industry, Respiratory disease, Leishmaniasis, General Medicine, Coronary Artery Disease, medicine.disease, Pancytopenia, Kidney Transplantation, Surgery, Transplantation, Pneumonia, Visceral leishmaniasis, Nephrology, medicine, Humans, Leishmaniasis, Visceral, Coronary Artery Bypass, business, Tuberculosis, Pulmonary, Kidney transplantation, Rare disease
الوصف: Visceral leishmaniasis (VL) is an acute or subacute disease that is almost invariably fatal if untreated. It is a rare disease in renal transplant recipients and frequently reported together with other infectious agents. A 39-year-old renal transplant patient was admitted to hospital for elective coronary surgery. In the post-operative period, he developed spiking fever and non-productive cough and his general condition deteriorated. While he was taking medication for non-specific pneumonia, a cavitary lesion occurred in his lung, and he had the diagnosis of pulmonary tuberculosis and antituberculous treatment was started. Despite treatment, his fever continued. As the patient developed pancytopenia and splenomegaly, a bone marrow aspiration was done. Evaluation of bone marrow aspirate indicated Leishmania parasites. He was successfully treated with a more intensive liposomal amphotericin (L-AmB). Complete cure was achieved during follow-up period of 10 months without clinical relapse. In the existence of fever and long-standing pancytopenia, VL should be suspected although the patient had another proved infection and did not live or visit an endemic area. L-AmB usage can be safely preferred for treatment of selected renal transplant recipients with VL as first-line therapy.
تدمد: 0301-0430
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc1614cebfca0222e8eed9582c47a179
https://pubmed.ncbi.nlm.nih.gov/14579946
رقم الأكسشن: edsair.doi.dedup.....bc1614cebfca0222e8eed9582c47a179
قاعدة البيانات: OpenAIRE